Awaiting development: Guidance and quality standards

Showing 231 to 240 of 306

Guidance and quality standards awaiting development
Title	Type
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [TSID12341]	Technology appraisal guidance
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]	Technology appraisal guidance
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6635]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Setrusumab for treating osteogenesis imperfecta [TSID12308]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Sigvotatug vedotin for Non-small-cell lung cancer [TSID12335]	Technology appraisal guidance
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance